Open in Screener

PRME

Prime Medicine Inc

Aug 01 • 04:00PM ET

4.04

Dollar change +0.30
Percentage change 8.02	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT BEAM ALLO VERV DNLI IGMS PSTX SANA

| Held by: ARKG IWM VTI VXF IWN IBB SCHA VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-1.66	Insider Own	60.67%	Shs Outstand	131.16M	Perf Week	-4.04%
Market Cap	543.36M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	13.05%	Shs Float	52.90M	Perf Month	31.60%
Enterprise Value	520.25M	PEG	-	EPS next Q	-0.35	Inst Own	28.85%	Short Float	40.95%	Perf Quarter	132.18%
Income	-202.01M	P/S	141.13	EPS this Y	23.78%	Inst Trans	-5.46%	Short Ratio	5.75	Perf Half Y	42.76%
Sales	3.85M	P/B	4.96	EPS next Y	20.75%	ROA	-63.17%	Short Interest	21.66M	Perf YTD	38.36%
Book/sh	0.82	P/C	3.77	EPS next 5Y	18.47%	ROE	-115.21%	52W High	5.62 -28.11%	Perf Year	-25.60%
Cash/sh	1.07	P/FCF	-	EPS past 3/5Y	4.95% -124.13%	ROIC	-91.32%	52W Low	1.11 263.96%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-69.34%	Volatility	10.44% 12.63%	Perf 5Y	-
Dividend TTM	-	EV/Sales	135.13	EPS Y/Y TTM	22.37%	Oper. Margin	-5369.68%	ATR (14)	0.44	Perf 10Y	-
Dividend Ex-Date	Sep 10, 2019	Quick Ratio	4.78	Sales Y/Y TTM	550.76%	Profit Margin	-5252.50%	RSI (14)	56.10	Recom	1.73
Dividend Gr. 3/5Y	- -	Current Ratio	4.78	EPS Q/Q	9.47%	SMA20	-4.45%	Beta	2.41	Target Price	7.69
Payout	-	Debt/Eq	1.13	Sales Q/Q	146.02%	SMA50	46.10%	Rel Volume	1.24	Prev Close	3.74
Employees	214	LT Debt/Eq	1.07	Earnings	May 08 BMO	SMA200	51.12%	Avg Volume	3.77M	Price	4.04
IPO	Oct 20, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.59% -67.90%	Trades		Volume	4,693,890	Change	8.02%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Downgrade	Citigroup	Buy → Neutral	$1.50
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

Aug-01-25 04:01PM	Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.02%
Jul-31-25 11:40PM	JonesTrading Maintains a Buy on Prime Medicine (PRME) (Insider Monkey)
Jul-30-25 09:33PM	Prime Medicine Announces Pricing of Public Offering (GlobeNewswire)
04:01PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:55AM	Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:44AM	Loading…
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-20-25 12:35AM	BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT (Insider Monkey)
Jul-16-25 08:10AM	Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy (Business Wire) -5.83%
07:00AM	Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis (GlobeNewswire)
Jul-07-25 12:48PM	Prime Medicine stock soars amid gene editing sector momentum (Investing.com) +22.19%
Jul-06-25 04:01AM	Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data (Insider Monkey)
May-29-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-25 02:24PM	Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty (Insider Monkey)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks) +5.58%
May-19-25 08:31AM	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition (GlobeNewswire) -16.04%
08:30AM	Loading…
08:30AM	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease (GlobeNewswire)
08:28AM	Prime Medicine claims proof of concept, but lays off staff in pivot (BioPharma Dive)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.04%
08:00AM	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-25 05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.77%
May-05-25 08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.55%
Apr-25-25 10:51AM	Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 (Seeking Alpha)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -10.30%
Mar-20-25 06:48PM	Why Prime Medicine Stock Was Climbing Higher This Week (Motley Fool)
Mar-19-25 02:56PM	Why Prime Medicine Stock Is Soaring Today (Fool) +13.64%
Mar-18-25 08:09AM	Prime sets sights on liver, lung disease as next target for its gene editing tech (BioPharma Dive)
07:00AM	Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
01:00PM	Loading…
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-25-24 04:10AM	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio (Motley Fool)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks) +6.36% +6.64%
09:33AM	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target (MT Newswires)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Apr-23-24 08:00AM	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 08:45AM	2 Magnificent Growth Stocks With Room to Run (Motley Fool)
Mar-14-24 02:44PM	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging (InvestorPlace) -13.18%
Mar-01-24 02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
08:00AM	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) -5.99%
Feb-28-24 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:01PM	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.08% +5.73%
Feb-14-24 11:50PM	Prime Medicine Announces Pricing of Upsized Public Offering (GlobeNewswire) +13.62%
04:05PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-01-24 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +5.67%
Jan-25-24 08:00AM	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE Prime Editors for Cystic Fibrosis (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know (Zacks)
Jan-05-24 05:00PM	Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes (PR Newswire)
08:00AM	Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer (GlobeNewswire)
Jan-02-24 08:00AM	Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 10:30AM	Better Growth Stock: Archer Aviation or Prime Medicine? (Motley Fool) +6.73%
Nov-30-23 07:45AM	1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years (Motley Fool)
Nov-08-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire) -9.75%
Nov-03-23 04:01PM	Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +17.65%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 06:00AM	Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b (GlobeNewswire) -6.60%
Oct-24-23 07:30AM	Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases (GlobeNewswire)
05:04AM	The Bull Market Can Continue to Roll On; BMOs Brian Belski Predicts Further Gains for Stocks Here Are 3 Names to Play That Bullish Sentiment (TipRanks)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NELSEN ROBERT	Director	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:19 PM
ARCH Venture Partners XII, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:19 PM
ARCH Venture Partners X, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:18 PM
Liu David R.	10% Owner	Jun 30 '25	Buy	2.52	21,000	52,830	20,240,945	Jul 01 04:03 PM
Liu David R.	10% Owner	Jun 23 '25	Buy	2.16	21,000	45,402	20,219,945	Jun 23 04:33 PM
Liu David R.	10% Owner	Jun 16 '25	Buy	1.49	21,000	31,196	20,198,945	Jun 16 05:14 PM
Liu David R.	10% Owner	Jun 11 '25	Buy	1.60	21,000	33,590	20,177,945	Jun 12 04:49 PM
Brudnick Richard	Chief Business Officer	May 20 '25	Buy	1.19	20,000	23,790	20,000	May 22 04:22 PM
LEE ANN L.	Chief Technical Officer	May 21 '25	Buy	1.13	100,000	113,000	100,000	May 22 04:21 PM
Reine Allan	Chief Executive Officer	May 21 '25	Buy	1.18	125,000	147,150	125,000	May 22 04:18 PM

Open in Screener

MTSR

Metsera Inc

Aug 01 • 04:00PM ET

34.89

Dollar change +1.90
Percentage change 5.76	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM VTI VB XBI VXF VBR IWO VBK VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	51.74%	Shs Outstand	104.89M	Perf Week	-13.79%
Market Cap	3.67B	Forward P/E	-	EPS next Y	-3.58	Insider Trans	10.66%	Shs Float	50.70M	Perf Month	20.89%
Enterprise Value	3.14B	PEG	-	EPS next Q	-0.76	Inst Own	38.79%	Short Float	19.59%	Perf Quarter	49.36%
Income	-	P/S	-	EPS this Y	77.36%	Inst Trans	85.22%	Short Ratio	9.91	Perf Half Y	-
Sales	-	P/B	8.15	EPS next Y	-9.15%	ROA	-	Short Interest	9.93M	Perf YTD	31.66%
Book/sh	4.28	P/C	6.90	EPS next 5Y	32.19%	ROE	-	52W High	47.40 -26.39%	Perf Year	-
Cash/sh	5.05	P/FCF	-	EPS past 3/5Y	-1497.55% -	ROIC	-	52W Low	12.30 183.66%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.13% 10.53%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	3.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.46	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	-239.61%	SMA20	-8.79%	Beta	-	Target Price	57.33
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	7.06%	Rel Volume	2.06	Prev Close	32.99
Employees	81	LT Debt/Eq	0.00	Earnings	Jul 28 AMC	SMA200	23.78%	Avg Volume	1.00M	Price	34.89
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.29% -	Trades		Volume	2,059,729	Change	5.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-20-25	Initiated	Wells Fargo	Overweight	$65
Feb-25-25	Initiated	Guggenheim	Buy	$56
Feb-25-25	Initiated	Evercore ISI	Outperform
Feb-25-25	Initiated	BofA Securities	Buy	$38

Jul-28-25 04:01PM	Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress (GlobeNewswire) -5.73%
08:50AM	Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why (Zacks)
Jul-14-25 07:52AM	Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association (Insider Monkey) +8.12%
Jul-10-25 09:55AM	Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? (Zacks)
08:50AM	Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
09:55AM	Loading…
Jun-24-25 09:55AM	Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? (Zacks)
Jun-11-25 07:56PM	Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results (Insider Monkey) -5.81%
Jun-10-25 07:00AM	Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +15.50%
Jun-09-25 04:08PM	Obesity Newcomer Metsera Enters The Ring With A Punch And A Big Stock Jump (Investor's Business Daily) +10.55%
09:48AM	Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch (Investor's Business Daily)
08:06AM	Metsera shares climb on early data for amylin-targeting obesity shot (BioPharma Dive)
07:00AM	Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i (GlobeNewswire)
Jun-05-25 07:30AM	Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-12-25 07:00AM	Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress (GlobeNewswire) +10.52%
May-08-25 04:01PM	Metsera to Present at Bank of America 2025 Global Healthcare Conference (GlobeNewswire) +7.00%
08:50AM	Loading…
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-26-25 07:00AM	Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress (GlobeNewswire)
Mar-15-25 04:42PM	Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:13AM	Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Mar-03-25 02:50PM	Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey) +15.01%
Mar-01-25 05:02AM	Q4 2024 Amneal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 07:00AM	Metsera to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 02:04PM	Wall Street bullish on Metsera following January IPO on obesity drug pipeline (Investing.com) -8.32%
Feb-19-25 02:50PM	Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-05-25 04:01PM	Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
06:53PM	Metsera Announces Pricing of Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

Open in Screener

NMRA

Neumora Therapeutics Inc

Aug 01 • 04:00PM ET

1.56

Dollar change -0.40
Percentage change -20.41	%

Healthcare • Biotechnology • USA • NASD

NMRA Neumora Therapeutics Inc daily Stock Chart

Peers: BIIB VRTX NBIX AXSM ACAD SAGE ALKS BHVN PRTA AVXL

| Held by: VTI VXF SCHA IBB PRFZ VHT SCHB BTEC MSSM BIB

Index	-	P/E	-	EPS (ttm)	-1.61	Insider Own	59.69%	Shs Outstand	161.75M	Perf Week	-33.62%
Market Cap	252.33M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	-0.04%	Shs Float	65.21M	Perf Month	99.44%
Enterprise Value	2.70M	PEG	-	EPS next Q	-0.36	Inst Own	28.89%	Short Float	13.85%	Perf Quarter	102.23%
Income	-258.06M	P/S	-	EPS this Y	7.47%	Inst Trans	-15.60%	Short Ratio	6.21	Perf Half Y	-18.75%
Sales	0.00M	P/B	1.10	EPS next Y	30.37%	ROA	-73.01%	Short Interest	9.03M	Perf YTD	-85.28%
Book/sh	1.41	P/C	1.01	EPS next 5Y	14.67%	ROE	-79.05%	52W High	17.19 -90.92%	Perf Year	-87.82%
Cash/sh	1.55	P/FCF	-	EPS past 3/5Y	0.69% -	ROIC	-113.00%	52W Low	0.61 155.32%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.53% 18.65%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	0.76%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.98	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.37	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	8.98	EPS Q/Q	-24.92%	SMA20	-6.19%	Beta	2.95	Target Price	8.25
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	35.85%	Rel Volume	1.45	Prev Close	1.96
Employees	110	LT Debt/Eq	0.00	Earnings	Aug 06 AMC	SMA200	-62.05%	Avg Volume	1.46M	Price	1.56
IPO	Sep 15, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-12.42% -	Trades		Volume	2,108,992	Change	-20.41%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform	$1
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$29 → $4
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Show Previous Ratings

Jul-29-25 10:23AM	Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating (Insider Monkey)
Jul-23-25 07:00AM	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating (Insider Monkey)
Jul-09-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 (GlobeNewswire) +13.12%
May-13-25 03:10AM	Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ... (GuruFocus.com)
04:01PM	Loading…
May-12-25 04:01PM	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:00AM	Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-22-25 02:49AM	Former Neumora CEO to lead Galapagos spinout (BioPharma Dive) +6.82%
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
Mar-18-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-04-25 08:30AM	Neumora Therapeutics to Present at Leerink Global Healthcare Conference (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.94%
05:45AM	Loading…
Feb-28-25 05:45AM	Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-26-25 08:46PM	Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-18-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:00AM	Neumora Therapeutics Announces Leadership Transition (GlobeNewswire)
Feb-11-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire) -6.18%
Jan-04-25 08:00AM	Neumora shares look oversold after 80% drop, says Mizuho (TipRanks)
Jan-03-25 07:20AM	Neumora Therapeutics navacaprant did not meet primary endpoint in depression (TipRanks) +10.15%
Jan-02-25 05:07PM	Results are in for a new depression drug trial, and they're cratering this stock (Quartz) -81.42%
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
01:28PM	Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial (Insider Monkey)
01:07PM	Neumora shares sink following Phase III flop in MDD (Pharmaceutical Technology)
12:00PM	Top Stock Movers Now: Uber, Unity Software, Tesla, and More (Investopedia)
10:47AM	Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals (Investopedia)
09:59AM	Loading…
09:59AM	Stock in Biotech Neumora Plunges 80% as Depression Drug Fails (Barrons.com)
09:54AM	Neumora Plunges After Major Depression Drug Fails in Study (Bloomberg)
08:30AM	Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials (Benzinga)
07:00AM	Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder (GlobeNewswire)
Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henry Gosebruch	Officer	Mar 12 '25	Proposed Sale	1.43	15,000	21,450		Mar 12 04:49 PM
BERNS PAUL L	See Remarks	Feb 18 '25	Sale	1.69	13,871	23,468	7,405,004	Feb 20 05:14 PM
Milligan Michael Lee	See Remarks	Feb 18 '25	Sale	1.69	1,978	3,351	22,470	Feb 20 05:14 PM
Aurora Daljit Singh	Chief Strategy Officer	Feb 18 '25	Sale	1.68	8,565	14,347	88,935	Feb 20 05:13 PM
Lenz Robert A.	Head of R&D	Feb 18 '25	Sale	1.67	5,614	9,383	309,092	Feb 20 05:12 PM
Pinto Joshua	President	Feb 18 '25	Sale	1.67	8,048	13,477	76,952	Feb 20 05:11 PM
Suh Carol Y.	Officer	Feb 18 '25	Proposed Sale	1.68	9,540	16,020		Feb 18 05:51 PM
Milligan Michael Lee	Officer	Feb 18 '25	Proposed Sale	1.69	1,978	3,351		Feb 18 05:49 PM
Pinto Joshua	Officer	Feb 18 '25	Proposed Sale	1.67	8,048	13,478		Feb 18 05:45 PM
Lenz Robert A.	Officer	Feb 18 '25	Proposed Sale	1.67	5,614	9,383		Feb 18 05:43 PM
Gosebruch Henry O	Officer	Feb 18 '25	Proposed Sale	1.67	6,857	11,462		Feb 18 05:41 PM
BERNS PAUL L	Officer	Feb 18 '25	Proposed Sale	1.69	13,871	23,468		Feb 18 05:40 PM
Aurora Daljit Singh	Officer	Feb 18 '25	Proposed Sale	1.68	8,565	14,348		Feb 18 05:38 PM
Fust Matthew K	Director	Oct 18 '24	Option Exercise	5.29	14,049	74,309	34,149	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Option Exercise	6.81	7,739	52,730	27,839	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Sale	17.03	14,049	239,319	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Sale	17.01	7,739	131,643	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Proposed Sale	17.03	14,049	239,319		Oct 18 04:01 PM
Fust Matthew K	Director	Oct 17 '24	Proposed Sale	17.01	7,739	131,643		Oct 17 04:26 PM
Lenz Robert A.	Head of R&D	Oct 10 '24	Sale	15.09	8,260	124,603	314,706	Oct 11 04:10 PM
Lenz Robert A.	Head of R&D	Oct 09 '24	Sale	15.01	5,563	83,507	322,966	Oct 11 04:10 PM
Lenz Robert A.	Officer	Oct 10 '24	Proposed Sale	15.09	8,260	124,603		Oct 10 04:30 PM
Lenz Robert A.	Officer	Oct 09 '24	Proposed Sale	15.01	5,563	83,507		Oct 09 04:10 PM
Lenz Robert A.	Head of R&D	Sep 17 '24	Sale	11.81	30,788	363,736	339,205	Sep 19 04:35 PM
Lenz Robert A.	Head of R&D	Sep 18 '24	Sale	12.09	10,676	129,091	328,529	Sep 19 04:35 PM
Lenz Robert A.	Officer	Sep 18 '24	Proposed Sale	12.09	10,676	129,091		Sep 18 04:27 PM
Lenz Robert A.	Officer	Sep 17 '24	Proposed Sale	11.81	30,788	363,734		Sep 17 04:37 PM
Lenz Robert A.	Head of R&D	Sep 12 '24	Sale	11.43	32,948	376,665	369,993	Sep 16 04:05 PM
Lenz Robert A.	Officer	Sep 12 '24	Proposed Sale	11.43	32,948	376,665		Sep 12 05:18 PM
Pinto Joshua	Chief Financial Officer	Aug 27 '24	Sale	11.39	15,693	178,806	138,965	Aug 27 05:58 PM
Pinto Joshua	Chief Financial Officer	Aug 26 '24	Sale	11.78	31,642	372,588	154,658	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 22 '24	Sale	11.63	28,496	331,468	210,469	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 23 '24	Sale	11.59	24,169	280,005	186,300	Aug 26 06:17 PM
Pinto Joshua	Officer	Aug 22 '24	Proposed Sale	11.90	100,000	1,190,000		Aug 22 09:48 AM

PRME

Prime Medicine Inc

MTSR

Metsera Inc

NMRA

Neumora Therapeutics Inc

Upgrade your FINVIZ experience